GSK promises to cap price of its drugs in poorest countriesBMJ 2009; 338 doi: https://doi.org/10.1136/bmj.b686 (Published 18 February 2009) Cite this as: BMJ 2009;338:b686
- Andrew Jack
- 1Financial Times
GlaxoSmithKline, the United Kingdom based pharmaceutical group, has unveiled a series of policies to boost access to its drugs in poorer and richer countries alike (www.gsk.com/media/Witty-Harvard-Speech-Summary.pdf).
In a speech at Harvard Medical School last week, Andrew Witty laid out his approach for the first time since taking over as the company’s chief executive last spring, saying: “Society expects us to do more . . . To be frank, I agree. We have the capacity to do more and we can do more.”
Last May Mr Witty replaced Jean-Pierre Garnier, who had already earned plaudits for strengthening GSK’s commitment to making drugs affordable (BMJ 2008;336:1396 doi:10.1136/bmj.a397), after criticism at the start of the decade …